In early stage NSCLC, TANs have been shown not to be mainly immunosuppressive, but would rather stimulate T cell-mediated immunity through the production of co-stimulatory molecules enhancing proliferation of CD4+and CD8+ T cells [29, 30]. The gene discussed is CD4; the disease is non-small cell lung carcinoma.